https://mindmedicinelaw.com/briefing/sweden-launches-psychedelic-clinical-trial-for-social-anxiety-20261028-54537The Psychedelic Journalen2026-10-28T15:06:11.496457+00:00Sweden Launches Psychedelic Clinical Trial for Social Anxietysweden psychedelic trial, social anxiety disorder, filament health, clinical research, scandinavian drug policy, psilocybin studies, industry-academic partnerships, european medicines agency, mental health innovationhttps://mindmedicinelaw.com/briefing/addiction-neuroscience-and-psychedelics-mechanism-based-shifts-in-clinical-conte-20261027-54456The Psychedelic Journalen2026-10-28T15:07:04.057314+00:00Addiction Neuroscience and Psychedelics: Mechanism-Based Shifts in Clinical Contextaddiction neuroscience, psychedelics, mechanism-based treatment, clinical trials, public health policy, reward circuitry, opioid withdrawal, relapse prevention, translational researchhttps://mindmedicinelaw.com/briefing/ketamine-augmented-hypnotherapy-early-clinical-insights-and-research-needs-20261027-54457The Psychedelic Journalen2026-10-28T15:06:28.518024+00:00Ketamine-Augmented Hypnotherapy: Early Clinical Insights and Research Needsketamine-augmented hypnotherapy, kaht, psychedelic-assisted therapy, clinical trials, hypnotherapy, depression, neuroplasticity, patient safety, randomized controlled trialshttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-clinical-evidence-and-challenges-2020-2025-20261027-54441The Psychedelic Journalen2026-10-28T15:05:54.273006+00:00Psychedelic-Assisted Therapy: Clinical Evidence and Challenges (2020–2025)psychedelic-assisted therapy, clinical trials, MDMA, psilocybin, depression, PTSD, protocol heterogeneity, blinding, safety monitoring, ethicshttps://mindmedicinelaw.com/briefing/psychosis-risk-in-psychedelic-therapy-systematic-review-insights-global-1984-202-20261027-54455The Psychedelic Journalen2026-10-28T15:05:36.086901+00:00Psychosis Risk in Psychedelic Therapy: Systematic Review Insights (Global, 1984–2025)psychedelics, psychosis risk, systematic review, clinical trials, screening protocols, policy implications, public health, psychiatric safety, regulation, emergency datahttps://mindmedicinelaw.com/briefing/phmsa-s-proposed-hazmat-rule-impacts-on-psychedelic-research-supply-chains-20261027-54106The Psychedelic Journalen2026-10-27T15:05:30.039363+00:00PHMSA’s Proposed Hazmat Rule: Impacts on Psychedelic Research Supply Chainsphmsa, hazardous materials regulations, psychedelic research, international harmonization, chemical shipping, regulatory compliance, clinical trial logistics, federal register, supply chain riskhttps://mindmedicinelaw.com/briefing/media-coverage-of-psilocybin-outpaces-science-systematic-review-insights-20261027-54241The Psychedelic Journalen2026-10-27T15:05:14.437839+00:00Media Coverage of Psilocybin Outpaces Science: Systematic Review Insightspsilocybin media coverage, systematic review 2026, science communication, psychedelic policy, clinical trial reporting, public health risk, regulatory approval, hype in medicine, patient expectationshttps://mindmedicinelaw.com/briefing/australian-ketamine-trial-targets-emergency-worker-mental-health-20261027-54242The Psychedelic Journalen2026-10-27T15:04:55.410952+00:00Australian Ketamine Trial Targets Emergency Worker Mental Healthketamine trial australia, emergency service workers mental health, ptsd depression treatment, black dog institute research, psychedelic-assisted therapy, australian clinical trials, tga regulation, occupational mental health, ketamine safety riskshttps://mindmedicinelaw.com/briefing/neuroplasticity-as-a-therapeutic-target-in-depression-implications-for-psychedel-20261026-54458The Psychedelic Journalen2026-10-28T15:08:08.992042+00:00Neuroplasticity as a Therapeutic Target in Depression: Implications for Psychedelic Researchneuroplasticity, major depressive disorder, bdnf-trkb pathway, mtorc1 signaling, psychedelic research, clinical trial design, synaptogenesis, biomarkers, regulatory sciencehttps://mindmedicinelaw.com/briefing/striatal-plasticity-and-relapse-risk-in-anorexia-nervosa-implications-for-neurom-20261026-54470The Psychedelic Journalen2026-10-28T15:07:54.185945+00:00Striatal Plasticity and Relapse Risk in Anorexia Nervosa: Implications for Neuromodulatory Researchstriatal plasticity, anorexia nervosa relapse, putamen gradient, biomarkers, psychedelic-assisted therapy, neuromodulation, reward processing, clinical trials, brain imaging, habitual behaviorhttps://mindmedicinelaw.com/briefing/chemsex-emergencies-clinical-and-policy-challenges-for-ems-in-europe-20261026-54442The Psychedelic Journalen2026-10-28T15:07:36.915196+00:00Chemsex Emergencies: Clinical and Policy Challenges for EMS in Europechemsex, emergency medical services, public health, syndromic approach, polysubstance use, harm reduction, protocol development, operational risk, european policyhttps://mindmedicinelaw.com/briefing/whole-brain-modeling-and-subtype-specific-regulation-in-adolescent-mdd-20261026-54471The Psychedelic Journalen2026-10-28T15:07:19.583490+00:00Whole Brain Modeling and Subtype-Specific Regulation in Adolescent MDDadolescent depression, major depressive disorder, whole brain modeling, computational psychiatry, personalized neuromodulation, psychedelic clinical trials, neuroimaging biomarkers, subtype-specific interventionshttps://mindmedicinelaw.com/briefing/sex-differences-in-psilocybin-vs-escitalopram-for-mdd-bayesian-reanalysis-20261026-54421The Psychedelic Journalen2026-10-28T15:06:45.816607+00:00Sex Differences in Psilocybin vs. Escitalopram for MDD: Bayesian Reanalysispsilocybin, escitalopram, major depressive disorder, sex differences, bayesian analysis, psychedelic trials, clinical trial design, anxiety outcomes, sexual dysfunction, personalized psychiatryhttps://mindmedicinelaw.com/briefing/multiscale-interoceptive-medicine-and-psychedelic-mechanisms-implications-for-ne-20261026-54338The Psychedelic Journalen2026-10-27T22:05:36.228761+00:00Multiscale Interoceptive Medicine and Psychedelic Mechanisms: Implications for Neuroimmune Researchmultiscale interoceptive medicine, insular cortex, default mode network, psychedelic mechanisms, neuroimmune modulation, systems neuroscience, active inference, clinical trial design, psychiatric comorbidity, regulatory sciencehttps://mindmedicinelaw.com/briefing/pride-psilocybin-trial-screening-eligibility-gaps-in-italy-20261026-54337The Psychedelic Journalen2026-10-27T22:04:50.151806+00:00PRIDE Psilocybin Trial Screening: Eligibility Gaps in Italypride trial, psilocybin, treatment-resistant depression, clinical trial eligibility, external validity, psychedelic research, italy, screening data, precision psychiatryhttps://mindmedicinelaw.com/briefing/5-meo-dmt-from-toad-venom-clinical-trial-for-depression-in-2026-20261026-54065The Psychedelic Journalen2026-10-26T22:06:21.323921+00:005-MeO-DMT From Toad Venom: Clinical Trial for Depression in 20265-meo-dmt, toad venom, treatment-resistant depression, psychedelic clinical trials, fda guidance, psychiatric research, synthetic vs natural psychedelics, schedule i substances, ecological impact, psychedelic regulationhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-therapy-program-first-real-world-study-findings-20261026-54066The Psychedelic Journalen2026-10-26T22:06:01.559772+00:00Oregon’s Psilocybin Therapy Program: First Real-World Study Findingspsilocybin therapy, oregon health authority, psychedelic regulation, real-world evidence, mental health policy, facilitator training, adverse events, access disparities, clinical outcomes, state-level legalizationhttps://mindmedicinelaw.com/briefing/fda-leadership-issues-formal-policy-statement-on-psychedelics-20261026-54064The Psychedelic Journalen2026-10-26T22:05:42.070780+00:00FDA Leadership Issues Formal Policy Statement on Psychedelicsfda psychedelics policy, psychedelic drug approval, clinical trial design, therapist training requirements, regulatory risk, real-world evidence, psychedelic industry, post-marketing surveillance, mental health therapieshttps://mindmedicinelaw.com/briefing/self-compassion-in-mdma-assisted-therapy-for-social-anxiety-early-clinical-insig-20261025-53969The Psychedelic Journalen2026-10-26T22:06:38.826737+00:00Self-Compassion in MDMA-Assisted Therapy for Social Anxiety: Early Clinical Insightsmdma-assisted therapy, self-compassion, social anxiety disorder, psychedelic clinical trials, mechanisms of action, internalized shame, depressive symptoms, treatment moderators, trial design, psychological mechanismshttps://mindmedicinelaw.com/briefing/philosophical-audit-of-psychiatric-assumptions-in-psychedelic-therapy-research-20261024-54302The Psychedelic Journalen2026-10-27T22:05:58.083100+00:00Philosophical Audit of Psychiatric Assumptions in Psychedelic Therapy Researchpsychedelic-assisted therapy, psychiatric assumptions, clinical trial design, outcome measurement, regulatory standards, nosology, philosophy of psychiatry, process-based outcomes, FDA, research frameworkshttps://mindmedicinelaw.com/briefing/esketamine-use-and-postoperative-mental-health-in-elderly-chinese-patients-20261024-53997The Psychedelic Journalen2026-10-26T22:07:33.030878+00:00Esketamine Use and Postoperative Mental Health in Elderly Chinese Patientsesketamine, postoperative anxiety, postoperative depression, elderly patients, china, perioperative mental health, nmda antagonist, clinical trials, psychedelic research, public healthhttps://mindmedicinelaw.com/briefing/muscarinic-signaling-and-prefrontal-stm-implications-for-neuropsychiatric-drug-d-20261024-53996The Psychedelic Journalen2026-10-26T22:07:12.648937+00:00Muscarinic Signaling and Prefrontal STM: Implications for Neuropsychiatric Drug Developmentmuscarinic signaling, prefrontal cortex, short-term memory, thalamic drive, acetylcholine, neuropsychiatric therapeutics, cognitive enhancement, mechanistic neuroscience, psychedelic drug development, clinical trial designhttps://mindmedicinelaw.com/briefing/validated-recovery-curves-for-phq-8-and-gad-7-in-outpatient-care-20261024-53998The Psychedelic Journalen2026-10-26T22:06:56.508249+00:00Validated Recovery Curves for PHQ-8 and GAD-7 in Outpatient Caremeasurement-based care, phq-8, gad-7, recovery curves, psychedelic clinical trials, outpatient mental health, treatment failure prediction, depression endpoints, anxiety endpointshttps://mindmedicinelaw.com/briefing/psilocybin-for-major-depression-systematic-review-highlights-efficacy-and-safety-20261023-54303The Psychedelic Journalen2026-10-27T22:05:11.221051+00:00Psilocybin for Major Depression: Systematic Review Highlights Efficacy and Safetypsilocybin, major depressive disorder, systematic review, antidepressant effects, clinical trials, serotonin receptors, glutamate modulation, safety profile, regulatory policy, treatment-resistant depression